PT - JOURNAL ARTICLE AU - Tchen, John AU - Simon, Quentin AU - Chapart, Léa AU - Lamri, Yasmine AU - Saidoune, Fanny AU - Pacreau, Emeline AU - Pellefigues, Christophe AU - Bex-Coudrat, Julie AU - Karasuyama, Hajime AU - Miyake, Kensuke AU - Hidalgo, Juan AU - Fallon, Padraic G. AU - Papo, Thomas AU - Blank, Ulrich AU - Benhamou, Marc AU - Hanouna, Guillaume AU - Sacre, Karim AU - Daugas, Eric AU - Charles, Nicolas TI - Pathogenic accumulation of T follicular helper cells in lupus disease depends on PD-L1 and IL-4 expressing basophils AID - 10.1101/2023.01.10.23284399 DP - 2023 Jan 01 TA - medRxiv PG - 2023.01.10.23284399 4099 - http://medrxiv.org/content/early/2023/01/11/2023.01.10.23284399.short 4100 - http://medrxiv.org/content/early/2023/01/11/2023.01.10.23284399.full AB - Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibodies raised against nuclear antigens and whose production is promoted by autoreactive T follicular helper (TFH) cells. Basophils, by accumulating in secondary lymphoid organs (SLO), amplify autoantibody production and disease progression through mechanisms to be defined. Here, we demonstrate that a functional relationship between TFH cells and basophils occurs in SLO during lupus pathogenesis. On SLE patient blood basophils, PD-L1 expression was upregulated and associated with TFH and TFH2 cell expansions and with disease activity. In two distinct lupus-like mouse models, TFH cell pathogenic accumulation, maintenance and function, and disease activity were dependent on basophils and their expressions of PD-L1 and IL-4. Our study establishes a direct link between basophils and TFH cells in the SLE context that promotes autoreactive IgG production and lupus nephritis pathogenesis. Altering the basophil/TFH cell axis in the SLE context may represent a promising innovative intervention strategy in SLE.Competing Interest StatementN.C. holds a patent related to compositions and methods for treating or preventing lupus (W020120710042). C.P. and N.C. are coinventors of the patent WO2016128565A1 related to the use of PTGDR-1 and PTGDR-2 antagonists for the prevention or treatment of systemic lupus erythematosus. No other disclosures relevant to this article are reported.Funding StatementThis work was supported by the Fondation pour la Recherche Medicale (FRM) [grant # EQU201903007794] to N.C., the French Agence Nationale de la Recherche (ANR) [grants # ANR-19-CE17-0029 BALUMET to N.C. and ANRPIA-10-LABX-0017 INFLAMEX], the Ministerio de Economia y Competitividad y Fondo Europeo de Desarrollo Regional (RTI2018-101105-B-I00) to J.H., by the Centre National de la Recherche Scientifique (CNRS), by Universite Paris-Cite and by the Institut National de la Sante et de la Recherche Medicale (INSERM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Blood samples were collected from adult patients enrolled in a prospective long-term study of systemic lupus erythematosus (SLE) and chronic renal diseases. The ethics committee Comite de Protection des Personnes of the Agence Regionale de Sante Ile-de-France (CPP, Paris, France) gave ethical approval for this work under the reference ID-RCB 2014-A00809-38. SLE samples were obtained from in- and outpatients and clinical data were harvested after approval by the Commission Nationale de l'Informatique et des Libertes (CNIL). Written informed consent was obtained from all individuals.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors